RSS GSK's Shingrix New Prefilled Syringe Presentation Accepted For Review By FDA

Currently reading:
 RSS GSK's Shingrix New Prefilled Syringe Presentation Accepted For Review By FDA

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,936
Likes
1,923
Credits
33,627©
Cash
0$
GSK plc, the British pharmaceutical giant, has announced that the U.S. Food and Drug Administration (FDA) has commenced its review of a new regulatory submission for a prefilled syringe version of Shingrix, the Recombinant Zoster Vaccine (RZV), designed to prevent shingles, also known as herpes zoster.

This new prefilled syringe format, once approved, is expected to provide healthcare professionals with a more convenient method of vaccine administration. The FDA is anticipated to make a decision regarding this application by June 20.

Shingles is characterized by a painful, blistering rash that can persist for several weeks, triggered by the reactivation of the varicella-zoster virus (VZV)—the same virus responsible for chickenpox. By the age of 50, most adults carry the dormant VZV, which can reactivate with advancing age.

Shingrix is a non-live, recombinant subunit vaccine intended for the prevention of shingles in individuals aged 50 and above. The vaccine incorporates an antigen, glycoprotein E, alongside an adjuvant system, AS01B, to enhance vaccine efficacy, countering the natural decline in immune response associated with aging.

Currently, the vaccine is available as a combination of a lyophilized antigen (in powder form) and a liquid adjuvant, which require mixing before administration. The new prefilled syringe format eliminates the need to reconstitute these separate components, simplifying the vaccination process for healthcare providers.

GSK affirms that this new formulation contains the same ingredients as the reconstituted version, with the regulatory submission supported by data affirming its comparability.

Since 2017, Shingrix has been approved in the U.S. for preventing shingles in adults aged 50 and older. In 2021, its approval was extended to adults 18 years and older who are at heightened risk of shingles due to immunodeficiency or immunosuppression from disease or therapy.

It is important to note that RZV is not intended to prevent the primary varicella infection, commonly known as chickenpox. In addition, RZV has gained approval in multiple countries for adults aged 18 and over who are at an increased risk of developing shingles.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom